Related Experiment Videos
Etoricoxib.
Alan K Matsumoto1, Paul F Cavanaugh
1Arthritis and Rheumatism Associates, Wheaton, Maryland 20902, USA. akmatsumoto@arapc.com
Drugs of Today (Barcelona, Spain : 1998)
|August 21, 2004
Summary
Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, offers effective pain and inflammation relief comparable or superior to nonselective NSAIDs. It provides improved gastrointestinal safety and a favorable tolerability profile for various conditions.
Area of Science:
- Pharmacology
- Rheumatology
- Pain Management
Background:
- Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, belonging to the coxib class of nonsteroidal anti-inflammatory drugs (NSAIDs).
- COX-2 inhibition is a key mechanism for managing pain and inflammation.
- Nonselective NSAIDs carry risks of gastrointestinal adverse events.
Purpose of the Study:
- To review preclinical and clinical data on etoricoxib's efficacy and safety.
- To summarize etoricoxib's role in managing various pain and inflammatory conditions.
- To provide insights into etoricoxib's clinical application and dosing.
Main Methods:
- Review of published preclinical studies.
- Analysis of extensive clinical trial data.
- Summary of etoricoxib's pharmacokinetic and pharmacodynamic properties.
Main Results:
- Etoricoxib demonstrates analgesic and anti-inflammatory efficacy comparable or superior to nonselective NSAIDs.
- Improved gastrointestinal safety profile compared to nonselective NSAIDs.
- Rapid absorption, long half-life enabling once-daily dosing, and favorable overall safety.
Conclusions:
- Etoricoxib is an effective treatment option for osteoarthritis, rheumatoid arthritis, chronic low back pain, acute pain, gouty arthritis, and dysmenorrhea.
- Its favorable safety and tolerability profile, coupled with convenient dosing, support its clinical use.
- The review consolidates evidence supporting etoricoxib's therapeutic value in diverse patient populations.